Prosecution Insights
Last updated: April 19, 2026

La Jolla Institute For Allergy And Immunology

3 pending office actions

Portfolio Summary

3
Total Pending OAs
1
Final Rejections
2
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18094151 LIGHT INHIBITORS FOR SCLERODERMA AND SKIN FIBROTIC DISEASE TREATMENT WEN, SHARON X 1641 Final Rejection Jan 06, 2023
17048059 MODULATING IMMUNE RESPONSE VIA TARGETING OF OLFACTORY RECEPTOR ACTIVITY CHERNYSHEV, OLGA N 1675 Non-Final OA Oct 15, 2020
16765783 USE AND PRODUCTION OF ENGINEERED IMMUNE CELLS TO DISRUPT NFAT-AP1 PATHWAY TRANSCRIPTION FACTORS GONZALES, JOSEPHINE MARIA 1631 Non-Final OA May 20, 2020

Managing La Jolla Institute For Allergy And Immunology's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month